Every 8-K that Cerus Corp (CERS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CERS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CERS filings page.
Cerus Corporation reported Q2 2026 total revenue of $63.3 million, up 5% year over year, with product revenue of $57.4 million growing 10% and broad-based strength across product categories. INTERCEPT Fibrinogen Complex demand rose about 20%, and U.S. IFC sales reached $6.7 million versus $5.6 million.
Product gross profit was $29.5 million, though product gross margin declined to 51.4% from 55.2% due to currency and higher costs. Operating expenses fell 7% to $37.3 million, helping narrow net loss attributable to Cerus to $2.9 million, or $0.01 per share, while non-GAAP adjusted EBITDA improved to a positive $3.0 million.
Cash, cash equivalents and short-term investments totaled $56.3 million, with $35.0 million outstanding on the term loan and $30.1 million drawn on the revolver after a refinancing that reduced the term loan by $30 million. A BARDA contract expansion added $21.9 million of potential value to support INTERCEPT Red Blood Cell development. Management raised 2026 product revenue guidance to $229–$231 million, including higher IFC guidance of $23–$25 million, implying 11–12% and roughly 40–50% growth from 2025.
Cerus Corporation updated the employment terms for William “Obi” Greenman following his transition from President, Chief Executive Officer and Chairman to Executive Chairman effective July 1, 2026. Under an amendment to his employment letter, he will serve as Executive Chairman through May 31, 2027, with an anticipated time commitment averaging about 60% of a full-time schedule, unless earlier terminated or extended by written agreement. For this role, he will receive an annual base salary of $500,000 and, for 2026, will be eligible for an annual cash bonus with a target opportunity equal to 80% of his total 2026 base salary. He will not be entitled to earn an annual cash bonus for any portion of 2027. If his change in role triggers a qualifying event under the Consolidated Omnibus Reconciliation Act, Cerus will pay or reimburse his COBRA health insurance premiums, subject to his continued compliance with the amended letter agreement and his timely COBRA election. All other terms of the original letter agreement remain unchanged.
Cerus Corporation entered into new secured credit agreements that refinance and expand its debt facilities. The term loan agreement provides up to $65.0 million, of which $35.0 million was drawn on closing to refinance existing term loans, after having repaid $30.0 million under the prior term facility. An additional $30.0 million term tranche may be requested in minimum $5.0 million increments for working capital and general corporate purposes.
The revolving credit agreement provides an initial $30.0 million borrowing base-driven revolver, with potential to increase commitments by $15.0 million. As of the closing date, $29.9 million was outstanding. Term loans bear interest at Term SOFR plus 5.50%, and revolver borrowings at Term SOFR plus 3.70%, each with a 1.00% SOFR floor. Cerus’s obligations are secured by substantially all assets and are subject to revenue-based financial covenants and customary negative covenants and events of default.
Cerus Corporation reported results from its 2026 Annual Meeting of Stockholders. Shareholders approved an amendment and restatement of the 2024 Equity Incentive Plan, increasing the common stock available for issuance under the plan by 10,000,000 shares.
Stockholders also elected William M. Greenman and Ann Lucena to the board to serve until the 2029 Annual Meeting. In additional votes, shareholders approved on an advisory basis the compensation of named executive officers and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Cerus Corporation reported strong first quarter 2026 results with higher revenue and a sharply lower net loss. Total revenue was $59.9 million, up 23% from $48.9 million a year earlier, driven by 24% product revenue growth to $53.7 million and 120% demand growth for INTERCEPT Fibrinogen Complex.
Product gross profit rose to $27.9 million, though product gross margin declined to 52.0% from 58.8% due to prior-year one-time benefits and current inflation, currency, and tariff impacts. Operating expenses fell 7% to $34.5 million, helping reduce net loss attributable to Cerus to $1.6 million, or $0.01 per share, from $7.7 million, or $0.04 per share.
The company generated non-GAAP adjusted EBITDA of $4.0 million versus $0.2 million a year earlier and ended March 31, 2026 with $80.4 million in cash, cash equivalents, and short-term investments. Cerus raised its 2026 product revenue guidance to a range of $227 million to $231 million, including IFC revenue between $22 million and $24 million, reflecting expected growth of 10% to 12% from 2025.
Cerus Corporation adopted a new executive severance plan that standardizes payouts for several senior officers if they are terminated without cause or resign for good reason, particularly around a change of control. The plan covers the CFO, COO, Chief Medical Officer and Chief Legal Officer.
Following a qualifying termination within 12 months after a change of control, participants receive a lump sum equal to 18 months of base salary and 1.5 times their target annual cash bonus, along with up to 18 months of paid COBRA premiums and full acceleration of all outstanding equity awards. For Vivek Jayaraman when serving as Chief Executive Officer, these change-of-control severance amounts increase to 24 months of base salary, two times target bonus and up to 24 months of COBRA.
Outside a change of control, the plan provides Mr. Green and Ms. Jensen (and Mr. Jayaraman while COO) with 12 months of salary continuation and up to 12 months of COBRA coverage. If Mr. Jayaraman is President and Chief Executive Officer at the time of a qualifying non-change-of-control termination, he also receives full equity acceleration and, for terminations after September 30, a prorated annual cash bonus based on his target opportunity and time worked.
Cerus Corporation has appointed Vivek Jayaraman, currently Chief Operating Officer, as its next President and Chief Executive Officer effective July 1, 2026. On that date, current CEO and Board Chair William “Obi” Greenman will transition to the role of Executive Chairman, and Jayaraman will join the Board.
Under a new letter agreement effective March 11, 2026, Jayaraman will receive an annual base salary of $740,000, a target annual bonus opportunity of up to 80% of base salary starting in 2027, and will be eligible for equity incentives. These include a promotion equity award with a target value of $2,000,000 (75% time-based and 25% performance-based restricted stock units) and a one-time promotional performance-based award with a target value of $1,000,000. The number of shares for these awards will be based on the 30-day average closing price of Cerus common stock, but not less than $2.50 per share for calculation purposes.
If Jayaraman is terminated without cause or resigns for good reason, he may receive 12 months of base salary, a prorated annual bonus in certain cases, up to 12 months of COBRA premium support or equivalent cash payments, and full vesting of unvested time-based and performance-based restricted stock units, including in connection with a qualifying change in control.
Cerus Corporation reported strong 2025 growth with total revenue of $233.8 million, up 16% from 2024. Product revenue rose 14% to $206.1 million, helped by expansion of its INTERCEPT platelet franchise and higher U.S. INTERCEPT Fibrinogen Complex (IFC) sales.
IFC revenue increased about 80% to $16.7 million, and total product gross profit reached $112.3 million with a 54.5% margin, slightly below last year. Net loss narrowed to $15.6 million (or $0.08 per share), while non-GAAP adjusted EBITDA improved to $9.5 million. Cerus ended 2025 with $82.9 million in cash, cash equivalents and short-term investments and generated $4.8 million in operating cash flow for the year. For 2026, the company reaffirms product revenue guidance of $224–$228 million, implying 9%–11% growth, including expected IFC revenue of $20–$22 million, or roughly 20%–30% growth.
Cerus Corporation reported that board member Timothy L. Moore, whose term expires at the 2026 annual meeting of stockholders, has informed the company that he will not stand for re-election at that meeting. The company states that Mr. Moore’s decision is not due to any disagreement with Cerus regarding its operations, policies, or practices. The filing does not indicate any immediate change to the current composition of the board, only that his service will conclude at the end of his present term.
Cerus Corporation reported that it has released preliminary product revenue results for the fourth quarter and full year ended December 31, 2025, along with an outlook, through a press release referenced in this report. These figures are described as preliminary, unaudited and subject to completion of the company’s normal financial closing procedures, and the final results may differ from these early estimates, with any differences potentially being material.
The company notes that its independent registered public accounting firm has not audited or reviewed these preliminary numbers and does not provide any assurance on them. Cerus emphasizes that the product revenue information should not replace full financial statements prepared under U.S. GAAP and cautions against placing undue reliance on the preliminary data. The information in this report and the accompanying press release is being furnished, rather than filed, and is not automatically incorporated into other SEC filings.
Cerus Corporation (CERS) reported its third-quarter 2025 results for the period ended September 30, 2025. The company furnished a press release titled “Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance” as Exhibit 99.1.
The information was furnished under Item 2.02 and is not deemed filed for liability purposes. An Inline XBRL cover page was included as Exhibit 104.
Cerus Corporation (CERS) filed a Form 8-K to announce a governance change effective June 16, 2025. Long-standing board chair Daniel N. Swisher, Jr. retired from the board and its committees with no reported disagreements over company matters. To maintain continuity, the board moved quickly on June 20 to promote CEO William M. Greenman to chair while appointing Frank Witney, Ph.D. as lead independent director. Both directors will serve in their existing board classes, expiring at the 2026 and 2027 annual meetings, respectively. No other operational or financial data were disclosed in the filing.
The change consolidates the CEO and chair roles, offset by the creation of a lead independent director position intended to preserve board oversight. Investors should view the update as a routine succession matter with limited immediate financial impact but modest corporate-governance implications.